DWA
ABVX

Dorsey Wright & Associates’s Abivax ABVX Stock Holding History

Dorsey Wright & Associates’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22M Sell
16,645
-6,807
-29% -$770K 0.38% 70
2026
Q1 		$2.61M Buy
23,452
+6,832
+41% +$809K 0.32% 78
2025
Q4 		$2.24M Buy
+16,620
New +$1.81M 0.48% 68

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dorsey Wright & Associates's ABVX Position: Q2 2026 in Review

Dorsey Wright & Associates reduced its Abivax (ABVX) stake by 29% in Q2 2026, selling an estimated $770K and leaving 16,645 shares worth $2.22M. The position accounts for 0.38% of the portfolio, ranked #70.

Dorsey Wright & Associates first reported a position in ABVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.61M in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Dorsey Wright & Associates held 16,645 shares of Abivax worth $2.22M as of Q2 2026.
  • Dorsey Wright & Associates sold 6,807 Abivax shares in Q2 2026, an estimated $770K.
  • Abivax made up 0.38% of Dorsey Wright & Associates's portfolio in Q2 2026, its #70 holding.
  • Dorsey Wright & Associates first reported a position in Abivax in Q4 2025 and has held it in 3 quarters since.
  • Dorsey Wright & Associates's Abivax position peaked at $2.61M in Q1 2026.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Dorsey Wright & Associates's 13F filing for Q2 2026, filed 6 Aug 2026.